United Stateskyowakirin.com/biowa
BioWa, Inc. is a biotechnology company headquartered in Princeton, New Jersey, and a wholly owned subsidiary of Kyowa Kirin Co., Ltd. Incorporated in Delaware in 2003, BioWa serves as the exclusive worldwide licensor of Kyowa Kirin's proprietary therapeutic antibody technologies, including POTELLIGENT® and COMPLEGENT®.
POTELLIGENT® Technology enables the production of 100% fucose-free monoclonal antibodies, significantly enhancing antibody-dependent cellular cytotoxicity (ADCC) for improved anti-tumor activity. COMPLEGENT® Technology boosts complement-dependent cytotoxicity (CDC) through isotype chimerism, and the two can be combined to create AccretaMab® antibodies with dual enhancements.
BioWa licenses these platforms to pharmaceutical and biotech companies to advance monoclonal antibody-based therapeutics against cancer and other diseases. The company operates in the biopharmaceutical sector, focusing on antibody engineering rather than chemical manufacturing.
None yet. When a new project in the record names BioWa as owner, partner or investor, it shows here.
Approved with bortezomib+dexamethasone for adults after ≥1 prior line; DREAMM‑7: 3x PFS (36.6 vs 13.4m) and 42% lower death risk; outpatient ADC; ocular AEs manageable.
